Dr. Ayd has more than 35 years of experience in strategic planning, research & development, regulatory strategy, and operations within the Biopharma Industry. She leads the development and execution of LBG’s strategic regulatory and clinical services sector. Dr. Ayd is an expert in product development of small molecule and therapeutic protein drugs and drug/device combination products and also provides subject matter expertise in mergers and acquisition, business development, and due diligence. Dr. Ayd is an entrepreneurial-minded executive and Board Director who has a passion for helping companies envision success while leveraging her knowledge to guide effective execution. She helps our clients navigate complex government regulations and stay compliant with them.
Dr. Ayd is both a product development expert and trusted advisor to life sciences companies as they move from the nonclinical stage, through clinical development, marketing approval, product launch and into lifecycle management. Dr. Ayd assists key decision makers in optimizing their drug pipelines/portfolios whether organically or through M&A activity. She is indication-agnostic and supports small molecules, drug/device combination products, biosimilars, and therapeutic proteins. Dr. Ayd has a proven track record of value creation, having overseen ~90 drug application submission approvals globally which have generated billions of dollars.
Prior to joining Latham BioPharma Group, Dr. Ayd was CEO at Ayd BioPharma Consulting Group, LLC., a boutique consulting firm that provides technical support and expert advice to emerging and commercial Life Sciences companies regulated by the US FDA. As Vice President, Innovation & Development and member of the executive leadership within Fresenius-Kabi (FRE:DAX), Dr. Ayd was responsible for delivery of a pipeline of sterile injectable drugs valued at ~$5B in North America. In her role as Global Vice President and member of the “Top 50” executives at Hospira (HSP:NYSE) now Pfizer (PFE:NYSE), Dr. Ayd led the R&D-focused due diligence effort in notable M&A deals including the $2B acquisition of Mayne Pharma Ltd. and $0.5B acquisition of Orchid Pharmaceuticals (BSE: 524372, NSE:ORCHIDCHEM). Following the Orchid deal closure, she oversaw the brick & mortar build out of a new R&D center in India, hired staff and integrated them into an international product development team spanning four continents. Dr. Ayd’s experience also includes startups such as Advances Life Sciences (ADLS:NASDAQ) where she was Chief Operating Officer and Pinnacle Biologics where she was Chief Scientific Officer.
In addition to her role at LBG, Dr. Ayd is an Adjunct Professor of Law at Northwestern University, Pritzker School of Law and an adjunct Clinical Professor at The University of Wisconsin – Madison, School of Pharmacy. She is an Independent Board Director at Reglagene Holdings and a member of the Drug Discovery Institute’s Scientific Advisory Board at The Ohio University’s Cancer Center.
Dr. Ayd earned a Ph.D., in Pharmaceutics and Pharmacodynamics from The University of Illinois – Chicago, an MBA from Lewis University and a BS in Chemistry and Biology from Northeastern Illinois University.
